These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 5635365)

  • 1. Sparing action of uridine on the activity of arabinosylcytosine with normal and leukemic mice.
    Saslaw LD; Grindey GB; Kline I; Waravdekar VS
    Cancer Res; 1968 Jan; 28(1):11-20. PubMed ID: 5635365
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of uracil derivatives on phosphorylation of arabinosylcytosine.
    Grindey GB; Saslaw LD; Waravdekar VS
    Mol Pharmacol; 1968 Jan; 4(1):96-103. PubMed ID: 5640783
    [No Abstract]   [Full Text] [Related]  

  • 3. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
    Neil GL; Moxley TE; Manak RC
    Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analogs of 1-beta-D-arabinofuranosylcytosine. Studies on mechanisms of action in Burkitt's cell culture and mouse leukemia, and in vitro deamination studies.
    Dollinger MR; Burchenal JH; Kreis W; Fox JJ
    Biochem Pharmacol; 1967 Apr; 16(4):689-706. PubMed ID: 6033789
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of combined therapy with cytosine arabinoside (NSC-63878) and l,3-bis-(2-chloroethyl)-1-nitrosourea (NSC-409962) on sarcoma 180 and L1210 in vivo.
    Mizuno NS; Humphrey EW
    Cancer Chemother Rep; 1969 Sep; 53(4):215-21. PubMed ID: 5384462
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
    Klubes P; Cerna I
    Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory potency of 5-benzyluracil, 5-phenylcytosine and 5-phenylpyrimidin-2-one nucleosides against uridine phosphorylase from mouse leukemic L1210 cells.
    Votruba I; Krecmerová M; Hrebabecký H; Holý A
    Nucleosides Nucleotides; 1999; 18(11-12):2551-64. PubMed ID: 10639754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
    Rose WC; Trader MW; Laster WR; Schabel FM
    Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytidine 5'-triphosphate synthetase as a target for inhibition by the antitumor agent 3-deazauridine.
    McPartland RP; Wang MC; Bloch A; Weinfeld H
    Cancer Res; 1974 Nov; 34(11):3107-11. PubMed ID: 4472653
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
    Avery TL; Roberts D
    Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479
    [No Abstract]   [Full Text] [Related]  

  • 12. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia.
    Li LH; Olin EJ; Buskirk HH; Reineke LM
    Cancer Res; 1970 Nov; 30(11):2760-9. PubMed ID: 5487063
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma half-life of cytosine arabinoside in patients with leukaemia--the effect of uridine.
    Baguley BC; Falkenhaug EM
    Eur J Cancer (1965); 1975 Jan; 11(1):43-9. PubMed ID: 1055682
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of mitotic cycle inhibitors on the antileukemic activity of cytosine arabinoside (NSC-63878) in mice bearing leukemia L1210.
    Vadlamudi S; Goldin A
    Cancer Chemother Rep; 1971 Dec; 55(5):547-55. PubMed ID: 5159846
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunosuppressive activity of methotrexate and arabinosyl cytosine in mice bearing L1210 leukaemia.
    Baldini L; Brambilla G; Cavanna M; Parodi S
    Br J Pharmacol; 1968 Nov; 34(3):674P-676P. PubMed ID: 5726804
    [No Abstract]   [Full Text] [Related]  

  • 16. Scheduling of arabinosylcytosine and 6-thioguanine therapy.
    LePage GA; White SC
    Cancer Res; 1973 May; 33(5):946-9. PubMed ID: 4703126
    [No Abstract]   [Full Text] [Related]  

  • 17. Thymine starvation by inhibition of uptake and synthesis of thymine-compounds in Tetrahymena.
    Zeuthen E
    Exp Cell Res; 1968 Apr; 50(1):37-46. PubMed ID: 5650862
    [No Abstract]   [Full Text] [Related]  

  • 18. Studies of 6-N-hydroxylamino-9-beta-D-ribofuranosylpurine in mouse leukemia.
    Burchenal JH; Dollinger M; Butterbaugh J; Stoll D; Giner-Sorolla A
    Biochem Pharmacol; 1967 Mar; 16(3):423-8. PubMed ID: 6034363
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of combination treatment with 5-azacytidine and cytidine on the life-span and spleen and bone marrow cells of leukemic (L1210) and nonleukemic mice.
    Vadlamudi S; Choudry JN; Waravdekar VS; Kline I; Goldin A
    Cancer Res; 1970 Feb; 30(2):362-9. PubMed ID: 5458970
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolism of 1-beta-D-arabinofuranosylcytosine in leukemia L1210: studies with intact cells.
    Shrecker AW; Urshel MJ
    Cancer Res; 1968 Apr; 28(4):793-801. PubMed ID: 5649066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.